Andrea Jean Bourdelais
Psychologist in Wilmington, NC
License number
North Carolina 2244
Issued Date
May 21, 1999
Renew Date
Oct 1, 2004
Category
Psychological Associate
Address
Address
Wilmington, NC
Professional information
Polyether Brevetoxin Derivatives As A Treatment For Cystic Fibrosis, Mucociliary Dysfunction, And Pulmonary Diseases
US Patent:
7399782, Jul 15, 2008
Filed:
Sep 20, 2004
Appl. No.:
10/945467
Inventors:
Daniel G. Baden - Wilmington NC, US
William M. Abraham - Miami FL, US
Andrea J. Bourdelais - Wilmington NC, US
William M. Abraham - Miami FL, US
Andrea J. Bourdelais - Wilmington NC, US
Assignee:
University of North Carolina at Wilmington - Wilmington NC
International Classification:
A61K 31/335
US Classification:
514450
Abstract:
Disclosed are compounds that are derivatives of brevetoxin, or PbTx, pharmaceutical formulations comprising the compounds, and methods of regulating mucus transport in a cell, treating mucociliary dysfunction and diseases related to decreased mucus transport, wherein the compounds are of the Formula (I), and Formula (III):.
Polyether Brevetoxin Derivatives As A Treatment For Cystic Fibrosis, Mucociliary Dysfunction, And Pulmonary Diseases
US Patent:
2009001, Jan 15, 2009
Filed:
Jul 15, 2008
Appl. No.:
12/173286
Inventors:
Daniel G. Baden - Wilmington NC, US
William M. Abraham - Miami FL, US
Andrea J. Bourdelais - Wilmington NC, US
William M. Abraham - Miami FL, US
Andrea J. Bourdelais - Wilmington NC, US
International Classification:
C07D 493/22, A61K 31/366, A61K 31/352, A61P 11/00
US Classification:
514450, 549354, 549275
Abstract:
Disclosed are compounds that are derivatives of brevetoxin, or PbTx, pharmaceutical formulations comprising the compounds, and methods of regulating mucus transport in a cell, treating mucociliary dysfunction and diseases related to decreased mucus transport, wherein the compounds are of the Formula (I), and Formula (III):wherein R, R, R, R, A, n, and Y are as defined herein for each compound.
Fused Pentacyclic Polyethers
US Patent:
7638500, Dec 29, 2009
Filed:
Apr 10, 2007
Appl. No.:
11/733601
Inventors:
Daniel G. Baden - Wilmington NC, US
William M. Abraham - Miami FL, US
Andrea J. Bourdelais - Wilmington NC, US
Sophie Michelliza - Carolina Beach NC, US
William M. Abraham - Miami FL, US
Andrea J. Bourdelais - Wilmington NC, US
Sophie Michelliza - Carolina Beach NC, US
Assignee:
University of North Carolina at Wilmington - Wilmington NC
International Classification:
A61K 31/7072, A61K 31/52, A61K 31/4433, A61K 31/42, A61K 31/353
US Classification:
514 49, 514 50, 514394, 514450, 514378
Abstract:
Disclosed are polycyclic polyether compounds of formula I and pharmaceutical compositions comprising such compounds. Also disclosed are methods of regulating mucus clearance in a cell, and methods of treating decreased mucus clearance or mucociliary dysfunction.
Fused Pentacyclic Polyethers
US Patent:
8609628, Dec 17, 2013
Filed:
Jan 23, 2012
Appl. No.:
13/356312
Inventors:
Daniel G. Baden - Wilmington NC, US
William M. Abraham - Miami FL, US
Andrea J. Bourdelais - Wilmington NC, US
Sophie Michelliza - Carolina Beach NC, US
William M. Abraham - Miami FL, US
Andrea J. Bourdelais - Wilmington NC, US
Sophie Michelliza - Carolina Beach NC, US
Assignee:
University of North Carolina at Wilmington - Wilmington NC
International Classification:
A01N 43/04, A61K 31/517, A61K 31/505, A61K 31/42, A61K 31/415
US Classification:
514 49, 514 50, 514394, 514378, 514269, 514263
Abstract:
Disclosed are polycyclic polyether compounds of formula I and pharmaceutical compositions comprising such compounds. Also disclosed are methods of regulating mucus clearance in a cell, and methods of treating decreased mucus clearance or mucociliary dysfunction.
Fused Pentacyclic Polyethers
US Patent:
2005014, Jul 7, 2005
Filed:
Sep 20, 2004
Appl. No.:
10/945471
Inventors:
Daniel G. Baden - Wilmington NC, US
William Abraham - Miami FL, US
Andrea Bourdelais - Wilmington NC, US
William Abraham - Miami FL, US
Andrea Bourdelais - Wilmington NC, US
Assignee:
University of North Carolina - Wilmington NC
International Classification:
A61K031/7072, A61K031/42, A61K031/353, C07H019/04, C07D493/14
US Classification:
514050000, 514378000, 514450000, 536026100, 548240000, 549348000
Abstract:
Disclosed are polycyclic polyether compounds of formula I and pharmaceutical compositions comprising such compounds.
Fused Pentacyclic Polyethers
US Patent:
2010009, Apr 22, 2010
Filed:
Dec 22, 2009
Appl. No.:
12/644238
Inventors:
Daniel G. Baden - Wilmington NC, US
William M. Abraham - Miami FL, US
Andrea J. Bourdelais - Wilmington NC, US
Sophie Michelliza - Carolina Beach NC, US
William M. Abraham - Miami FL, US
Andrea J. Bourdelais - Wilmington NC, US
Sophie Michelliza - Carolina Beach NC, US
International Classification:
C07D 493/22, A61K 31/35, C12N 5/00, A61K 31/7076, A61K 31/7072, C07H 19/20, C07H 19/06, A61P 31/04, A61P 11/12, A61P 11/06
US Classification:
514 48, 549354, 514450, 435375, 5462827, 5483051, 514395, 514 51, 536 2626
Abstract:
Disclosed are polycyclic polyether compounds of formula I and pharmaceutical compositions comprising such compounds.Also disclosed are methods of regulating mucus clearance in a cell, and methods of treating decreased mucus clearance or mucociliary dysfunction.
Ladder-Frame Polyether Conjugates
US Patent:
2012007, Mar 29, 2012
Filed:
Sep 29, 2010
Appl. No.:
12/893344
Inventors:
Andrea Bourdelais - Wilmington NC, US
Daniel Baden - Wilmington NC, US
Allan Goodman - Wilmington NC, US
Steven Fontana - Wilmington NC, US
Daniel Baden - Wilmington NC, US
Allan Goodman - Wilmington NC, US
Steven Fontana - Wilmington NC, US
International Classification:
A61K 31/69, A01N 43/40, A01N 43/42, A61K 31/4188, A61K 31/35, C07D 491/147, C07D 491/22, C07D 495/04, C07F 5/02, C07D 493/22, A61K 31/437, A61K 31/4375, A01N 43/22, A01N 43/50, A01N 55/08, A01P 15/00, A61P 43/00, C12Q 1/02
US Classification:
514 64, 435 29, 514279, 514283, 514393, 514450, 546 37, 546 48, 5483037, 548405, 549354
Abstract:
Disclosed are compounds that are conjugates of ladder frame polyether compounds and biologically active compounds or research compounds, pharmaceutical formulations comprising the conjugates, and methods of transporting the conjugates across biological membranes.